Regeneron Pharmaceuticals Inc (REGN) Q1 2022
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2022 Earnings Conference
Regeneron Pharmaceuticals Inc. (REGN) Q4 2021 Earnings Call Transcript
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q4 2021 earnings call dated Feb. 04, 2022 Corporate Participants: Mark Hudson — Director, Investor Relations Leonard S. Schleifer — Founder, President and Chief…
Regeneron Pharmaceuticals Inc (REGN) Q3 2021 earnings conference call
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q3 2021 Earnings Conference
Regeneron Pharmaceuticals Inc (REGN) Q2 2021 Earnings Conference Call
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q2 2021 Earnings Conference
Regeneron Pharmaceuticals Inc. (REGN) Q1 2021 Earnings Call Transcript
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q1 2021 earnings call dated May. 06, 2021 Corporate Participants: Justin Holko — Vice President, Investor Relations Leonard S. Schleifer — Co-Founder, President and…
Regeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Conference Call
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2021 Earnings Conference
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2020 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Q4 2020 earnings call dated Feb. 05, 2021 Corporate Participants: Justin Holko — Vice President, Investor Relations Leonard S. Schleifer — Co-Founder, President and…
AlphaGraphs
Regeneron Pharmaceuticals (REGN) Q1 profit jumps 36%, beats estimates
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported a 36% jump in earnings for the first quarter of 2020 helped by higher revenue. The results exceeded analysts’…
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2019 Earnings Call Transcript
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2019 Earnings Conference Call Feb. 06, 2020 Corporate participants: Justin Holko — Investor Relations Leonard S. Schleifer — Founder,…
Market News
Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot
— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected. — Revenues grew 13% to $2.17 billion, vs. $2.11…